NEW ISSUE
LM revascularisation, annulus rupture, risk stratification, renal denervation
May 20, 2020
1. Division of Cardiology, CAST Policlinico Hospital, University of Catania, Catania, Italy; 2. McGill University Health Centre, Montreal, QC, Canada; 3. Barts Heart Centre, Queen Mary University of London, London, United Kingdom; 4. Department of Cardiology, Bern University Hospital “Inselspital”, Bern, Switzerland; 5. Klinik fur Herz- und Gefässchirurgie, UniversitatsSpital Zurich, Zurich, Switzerland; 6. Department of Cardiology, St Thomas’ Hospital, London, United Kingdom
The last decade has seen tremendous growth in transcatheter therapies for valvular heart disease (VHD), with 2019 being a special year embracing ground-breaking achievements. In particular, clinical evidence has now reached a level sufficient to support expanded indications for different transcatheter valve interventions, prompting the need to refine optimal patient management and device use further.
In the field of transcatheter aortic valve implantation (TAVI), two recent randomised clinical trials comparing TAVI with surgical aortic valve replacement (SAVR) extend the large body of evidence concerning these two procedures to patients at low surgical risk. In the PARTNER 3 trial1, transfemoral TAVI ...
Sign in to read and download the full article
Forgot your password?No account yet? Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com